The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group
Open accessAbstract
Purpose: To assess the predictive value of polymorphisms in dihydropyrimidine dehydrogenase (DPYD ), thymidylate synthase (TYMS ), and methylene tetrahydrofolate reductase (MTHFR ) and of nongenetic factors for severe leukopenia, diarrhea, and mucositis related to fluorouracil (FU) treatment. Patients and Methods: A multicenter prospective clinical trial included 683 patients with cancer treated with FU monotherapy. Toxicity was documented according to World Health Organization grades. DPYD, TYMS, and MTHFR genotypes were determined, and DPYD was resequenced in patients with severe toxicity. Results: Grade 3 to 4 toxicity occurred in 16.1% of patients. The sensitivity of DPYD*2A genotyping for overall toxicity was 5.5% (95%CI, 0.02 to 0.11), with a positive predictive value of 0.46 (95% CI, 0.19 to 0.75; P = .01). Inclusion of additional DPYD variants improved prediction only marginally. Analysis according to toxicity type revealed significant association of DPYD with mucositis and leukopenia, whereas TYMS was associated with diarrhea. Genotype, female sex, mode of FU administration, and modulation by folinic acid were identified as independent risk factors by multivariable analysis. A previously unrecognized significant interaction was found between sex and DPYD, which resulted in an odds ratio for toxicity of 41.8 for male patients (95% CI, 9.2 to 190; P < .0001) but only 1.33 (95% CI, 0.34 to 5.2) in female patients. Homozygosity for the TYMS enhancer region double repeat allele increased risk for toxicity 1.6-fold (95% CI, 1.08 to 2.22; P = .02). Conclusion: DPYD, TYMS, and MTHFR play a limited role for FU related toxicity but a pronounced DPYD gene/sex-interaction increases prediction rate for male patients. Toxicity risk assessment should include sex, mode of administration, and folinic acid as additional predictive factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Systemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.
Heggie, G. D., Sommadossi, J., Cross, D. S., Huster, W. J., & Diasio, R. B. (1987) · PubMed · Cited by 722
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
Pullarkat, S. T., Stoehlmacher, J., Ghaderi, V, Xiong, Y.-P., Ingles, S. A., Sherrod, A., Warren, R., Tsao-Wei, D., Groshen, S., & Lenz, H.-J. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500012 · Cited by 571
Horie, N., Aiba, H., Oguro, K., Hojo, H., & Takeishi, K. (1995) · Cell Structure and Function · doi:10.1247/csf.20.191 · Cited by 547
Diasio, R. B., Beavers, T. L., & Carpenter, J. T. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113308 · Cited by 503
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3537 · Cited by 495
Population study of dihydropyrimidine dehydrogenase in cancer patients.
Etienne, M. C., Lagrange, J. L., Dassonville, O., Fleming, R., Thyss, A., Renée, N., Schneider, M., Demard, F., & Milano, G. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2248 · Cited by 436
(2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.104 · Cited by 389
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
Wei, X., McLeod, H. L., McMurrough, J., Gonzalez, F. J., & Fernandez-Salguero, P. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118830 · Cited by 356
Women Experience Greater Toxicity With Fluorouracil-Based Chemotherapy for Colorectal Cancer
Sloan, J. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1491 · Cited by 262
Influence of sex and age on fluorouracil clearance.
Milano, G., Etienne, M. C., Cassuto-Viguier, E., Thyss, A., Santini, J., Frenay, M., Renee, N., Schneider, M., & Demard, F. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1171 · Cited by 260
Lecomte, T., Ferraz, J.-M., Zinzindohoué, F., Loriot, M.-A., Tregouet, D.-A., Landi, B., Berger, A., Cugnenc, P.-H., Jian, R., Beaune, P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0169 · Cited by 242
Morel, A., Boisdron-Celle, M., Fey, L., Soulie, P., Craipeau, M. C., Traore, S., & Gamelin, E. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0327 · Cited by 236
Fleming, R. A., Milano, G. A., Thyss, A., Étienne-Grimaldi, M.-C., Renée, N., Schneider, M., & Demard, F. (1992) · PubMed · Cited by 235
Raida, M., Schwabe, W., Häusler, P., Kuilenburg, A. B. P., Gennip, A. H., Behnke, D., & Höffken, K. (2001) · PubMed · Cited by 231
Rich, T. A., Shepard, R. C., & Mosley, S. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.009 · Cited by 212
Jakobsen, A., Nielsen, J. N., Gyldenkerne, N., & Lindeberg, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.219 · Cited by 191
Cohen, V., Panet-Raymond, V., Sabbaghian, N., Morin, I., Batist, G., & Rozen, R. R. (2003) · PubMed · Cited by 183
Mattison, L. K., Fourie, J., Desmond, R. A., Modak, A., Saif, M. W., & Diasio, R. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0747 · Cited by 174
Chansky, K., Benedetti, J., & Macdonald, J. S. (2005) · Cancer · doi:10.1002/cncr.20878 · Cited by 150
Dotor, E., Cuatrecases, M., Martínez‐Iniesta, M., Navarro, M., Vilardell, F., Guinó, E., Pareja, L., Figueras, A., Molleví, D. G., Serrano, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.5253 · Cited by 142
Étienne-Grimaldi, M.-C., Formento, J., Chazal, M., Francoual, M., Magn�, N., Formento, P., Bourgeon, A., Seitz, J.-F., Delpéro, J., Létoublon, C., et al. (2004) · Pharmacogenetics · doi:10.1097/00008571-200412000-00001 · Cited by 134
Johnson, M. R., Wang, K., & Diasio, R. B. (2002) · PubMed · Cited by 120
The oral fluoropyrimidines in cancer chemotherapy.
Lamont, E. B., & Schilsky, R. L. (1999) · PubMed · Cited by 113
Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda, H., Nishiyama, T., Ogura, K., Nagayama, S., Ikeda, K., Yamaguchi, S., Nakamura, Y., KAWAGUCHI, Y., Watabe, T., & Ogura, Y. (1997) · PubMed · Cited by 106
Ezzeldin, H. H., Lee, A. M., Mattison, L. K., & Diasio, R. B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1520 · Cited by 96
Relative Importance of Dose, Body Surface Area, Sex, and Age for 5-Fluorouracil Clearance
Port, R. E., Daniel, B., Ding, R. W., & Herrmann, R. (2009) · Oncology · doi:10.1159/000226942 · Cited by 67
Pharmacogenetics of folate-related drug targets in cancer treatment
Robien, K., Boynton, A., & Ulrich, C. M. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.7.673 · Cited by 67
Advances and Challenges in Fluoropyrimidine Pharmacogenomics and Pharmacogenetics
Soong, R., & Diasio, R. B. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.8.835 · Cited by 40
Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer
El-Rayes, B. F., Shields, A. F., Vaishampayan, U. N., Heilbrun, L. K., Bekaii‐Saab, T., Zalupski, M. M., & Philip, P. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3766 · Cited by 21
Cited by
Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., Klein, T. E., McLeod, H. L., Caudle, K. E., Diasio, R. B., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.911 · Cited by 694
Self-citationFunctional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593
Self-citationMucositis: The impact, biology and therapeutic opportunities of oral mucositis
Sonis, S. T. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2009.08.006 · Cited by 525
Gastric cancer: Classification, histology and application of molecular pathology.
Hu, B., Elhajj, N., Sittler, S. Y., Lammert, N., Barnes, R., & Meloni‐Ehrig, A. (2012) · PubMed · doi:10.3978/j.issn.2078-6891.2012.021 · Cited by 490
Circadian Timing in Cancer Treatments
Lévi, F., Okyar, A., Dulong, S., Innominato, P. F., & Clairambault, J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094626 · Cited by 476
Metadata
- Authors
- Schwab, M., Zanger, U. M., Marx, C., Schaeffeler, E., Klein, K., Dippon, J., Kerb, R., Blievernicht, J., Fischer, J., Hofmann, U., Bokemeyer, C., & Eichelbaum, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-05-01
- Volume
- 26
- Issue
- 13
- Pages
- 2131-2138
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2105763971
- Cited by
- 393
- References
- 31
- FWCI
- 27.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.